Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia

Yuxuan Wu1,2†, Xiangdong Du2*†, Ruchang Yang1,2, Yan Yue1,2, Ruijie Peng1,2, Siqi Wu3, Haitao Wang3, Yue Zhou2,4, Xiaojia Fang2,4, Nian Yuan2, Ronghua Li2, Jun Zhang2, Siyun Zou3, Xueli Zhao2, Xiaoli Lyu2, Zhe Li2, Xiaobin Zhang2 and Xiangyang Zhang5*

1 Suzhou Medical College of Soochow University, Suzhou, China, 2 Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University, Suzhou, China, 3 School of Psychology and Mental Health, North China University of Science and Technology, Tangshan, China, 4 Xuzhou Medical University, Xuzhou, China, 5 CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China

Previous studies have revealed that brain-derived neurotrophic factor (BDNF) levels are inversely associated with the severity of depressive symptoms. In addition, serum BDNF levels tend to increase with improvement in depressive symptoms. There is also evidence that BDNF has a possible role in the pathophysiology of schizophrenia. Therefore, the purpose of this study was to determine whether BDNF levels correlated with depressive symptoms in patients with first-episode and drug-naïve (FEDN) schizophrenia. In this study, 90 patients with FEDN schizophrenia and 60 healthy controls were recruited. The Positive and Negative Syndrome Scale (PANSS) and the 17-item Hamilton Depression Scale (HAMD-17) were used to gage psychopathological and depressive symptoms, respectively. All participants had their BDNF levels measured using a sandwich enzyme-linked immunosorbent test. Serum BDNF levels were lower in patients with FEDN schizophrenia compared with healthy controls. Moreover, patients with depressive symptoms exhibited a higher PANSS total score and a higher general psychopathology score than those without depressive symptoms ($p < 0.05$). For patients with depressive symptoms, serum BDNF levels were higher than in those without depressive symptoms ($p < 0.05$). An association between BDNF levels and the positive subscore was also observed ($p < 0.01$). However, there was no significant association between BDNF levels and HAMD scores ($p > 0.05$). In conclusion, BDNF levels were shown to be higher in the serum of patients with FEDN schizophrenia with depressive symptoms than in those without. Additionally, low levels of serum BDNF may contribute to the positive symptoms of FEDN schizophrenia but not to depressive symptoms.

Keywords: schizophrenia, depressive symptoms, brain-derived neurotrophic factor, first episode psychosis, serum
INTRODUCTION

Depressive symptoms are common in patients with first-episode schizophrenia, not only concurrent with, but also preceding, the first episode of schizophrenia (1). The prevalence of depressive symptoms among patients with schizophrenia has been estimated to range between 30 and 70% (2). Patients with schizophrenia are more likely to experience depressive symptoms than the general population (3). In addition, depressive symptoms typically manifest as hallmarks of schizophrenia and are associated with worse prognoses for schizophrenia (4, 5). Therefore, the quest for molecular biomarkers of depressive symptoms in schizophrenia is vital for the development of effective therapies to limit the detrimental consequences of depressive symptoms.

Brain-derived neurotrophic factor (BDNF), one of the most extensively distributed neurotrophins in the adult mammalian brain, plays a key role in supporting the dendrites of various central nervous system (CNS) neurons, such as mood-regulating neurons (6–9). According to previous studies, BDNF is implicated in the pathophysiology of schizophrenia and is associated with schizophrenia-related phenotypes (10, 11). A number of studies have shown that the serum BDNF levels of patients with schizophrenia were lower than those of healthy controls (12–15). In addition, serum BDNF levels have a substantial correlation with the Positive and Negative Syndrome Scale (PANSS) score (16). Furthermore, the mRNA expression of BDNF and tropomyosin receptor kinase B (TrkB) was found to be reduced in the prefrontal cortex and hippocampus of patients with schizophrenia, indicating that BDNF should be studied as a potential target for antipsychotic medications (17, 18).

In addition to schizophrenia, altered levels of BDNF in the hippocampus and blood have been associated with other psychiatric disorders, including depression (19, 20). For example, several animal studies have shown that BDNF appears to have a crucial role in depressive-like behavior in rats (21, 22). In human research, the description of BDNF levels in peripheral blood may be traced back to the early work of Karege, who suggested that major depression was characterized by low serum BDNF levels (23). According to increasing evidence, the interaction of BDNF-TrkB and dopamine (DA) signaling in midbrain circuits plays a major role in the pathophysiology of depression (24–26). There is also evidence that serum BDNF levels are decreased in depressed patients and recover to normal following antidepressant therapy (27, 28).

The association between depressive symptoms and BDNF in patients with schizophrenia has received limited research attention, despite the fact that many studies have investigated the associations between BDNF and memory and cognitive performance in schizophrenia (20, 29–31). According to an earlier study, the BDNF Val66Met polymorphism has been reported to affect the intensity of depressive symptoms in patients with schizophrenia (32). In addition, after 12 weeks of olanzapine medication, researchers found an increase in serum BDNF levels and a decline in depressive symptoms (33). Although Noto et al. reported that individuals with more severe depressive symptoms exhibited higher levels of BDNF (34), no research has studied the relationship between comorbid depression and BDNF in patients with first-episode schizophrenia. We therefore set out to explore whether BDNF is associated with depressive symptoms in patients with first-episode and drug-naïve (FEDN) schizophrenia.

MATERIALS AND METHODS

Participants

We recruited a total of 90 patients (48 men and 42 women) from Beijing Huilongguan Hospital, one of the largest public psychiatric hospitals in China. We diagnosed patients with schizophrenia up admission using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), and then we confirmed the diagnosis 12 weeks later (35). We defined patients as FEDN based on a previous study by Lieberman et al. (36). Inclusion criteria included: (1) age between 16 and 55 years; (2) acute episodes of DSM-IV schizophrenia at admission; (3) duration of symptoms ≤ 60 months; (4) never received any antipsychotic, antidepressant, or any other psychoactive treatment; (5) score ≥ 4 as assessed by the Clinical Global Impression-Severity scale (CGI-S); and (6) able to provide written informed consent. Upon admission, all patients were physically examined and provided a complete medical history. Among them, those meeting the following criteria were excluded: (1) current major physical illness; (2) personal history of neurological disorders; (3) history of alcohol or drug dependence in addition to smoking; and (4) inability to provide signed consent.

While the patients were being recruited, 60 healthy controls (31 men and 29 women) were recruited in the local community. Unstructured interviews and a personal and family psychiatric history were used to determine their current mental status. Individuals with a history of mental illness were barred from participating.

The research protocol was approved by the Institute Review Board, Beijing Huilongguan hospital. To be a part of the study, each participant had to complete an informed consent form.

Clinical Measures

The PANSS and the 17-item Hamilton Depression Scale (HAMD-17) were applied to measure psychopathology and depressive symptoms, respectively. Additionally, the clinical severity was assessed using the Clinical Global Impression Inventory (CGI). The PANSS, HAMD-17, and CGI evaluations were administered by four psychiatrists who had been trained in their usage prior to the commencement of the research to assure the reliability and consistency of the scales. After training, the correlation coefficient between investigators while repeatedly scoring the PANSS, HAMD-17, and CGI was more than 0.80.

The 17-item Hamilton Rating Scale for Depression (HAMD) was applied to assess depressive symptoms, with nine items scored from 0 (absent) to 2 (symptom-specific severity descriptors), and eight items scored from 0 (absent) to 4 (severe). Items 8, 9, and 11 were based on observation of the patient; the remaining items are assessed based on the patient’s own verbal narrative; item 1 required a combination of both. There were two other points to note: item 7 required information...
from the patient’s family, and item 16 could be assessed based on the patient’s complaint and information from the patient’s family. According to a previous study, we defined schizophrenia patients with depressive symptoms as having a total HAMD-17 score ≥ 8, while those without depressive symptoms had a total score ≤ 7 (37).

**Blood Sampling and Serum Brain-Derived Neurotrophic Factor Measurements**

Serum samples were collected from participants between 7:00 and 9:00 am after an overnight fast. In order to conduct the tests, samples were obtained on the same day as the clinical evaluation and separated, aliquoted, and stored at −70°C. A commercially available kit (R&D Systems, Beijing, China) was used to measure serum BDNF levels using a sandwich enzyme-linked immunosorbent assay. These assays are detailed in full in our prior reports (38, 39). The same technician, who had no knowledge of the clinical circumstances, measured all serum samples. Meanwhile, the principal investigator applied codes to identify all participants until all biochemical analyses were completed. The inter- and intra-assay coefficients of variation were 7 and 5%, respectively.

**Statistical Analysis**

First, the Kolmogorov-Smirnov one-sample test and the Q-Q plot were used to verify normality. For normally distributed numerical variables, mean ± standard deviation were used, whereas numbers and percentages were used for categorical variables. Demographic factors were compared using analysis of variance (ANOVA) for continuous variables and chi-square analysis for categorical variables. Demographic factors were compared using analysis of variance (ANOVA) for continuous variables and chi-square analysis for categorical variables. Furthermore, demographic parameters were taken into account as covariates in the comparison of serum BDNF levels between patients and healthy controls. The relationship between the variables was assessed with the Pearson’s product moment correlation method. In addition, further multiple linear regression analysis was used to explore correlations between the variables. All dependent variables were normally distributed and there was no evidence of multicollinearity.

We used SPSS (IBM SPSS 24.0, SPSS Inc.) and GraphPad Prism 8 (GraphPad Software Inc.) for all our analyses, with the significance level α set at p < 0.05 (two-tailed test).

**RESULTS**

**Comparison of Patients and Healthy Controls**

As shown in Table 1, each participant’s demographic, and clinical data were summarized. There was no significant sex difference between the patients with FEDN schizophrenia and healthy controls. However, the patients were younger than the healthy controls (p < 0.05).

| Variable | Schizophrenia (n = 90) | Healthy controls (n = 60) | F or X² | p-value |
|----------|-------------------------|--------------------------|---------|---------|
| Sex, M/F | 48/42                   | 31/29                    | 0.040   | 0.841   |
| Smokers, N (%) | 27 (30.0%)            | 22 (36.7%)             | 1.002   | 0.317   |
| Heredity |                         |                         |         |         |
| With, N (%) | 27 (30.0%)             |                         |         |         |
| Without, N (%) | 63 (70.0%)            |                         |         |         |
| Age, years | 29.1 ± 9.6             | 33.0 ± 9.8             | 5.77    | 0.017*  |
| BDNF, ng/ml | 9.1 ± 4.6              | 12.1 ± 1.7             | 21.076**| 0.000***|

**BDNF; brain-derived neurotrophic factor.**

*p < 0.05; **p < 0.001.

**TABLE 2 | Socio-demographic and clinical characteristics of the patients.**

| Variable | Schizophrenia | F or X² | P-value |
|----------|---------------|---------|---------|
| Sex, M/F | 16/14         | 32/28   | 0.000   | 1.000   |
| Smokers, N (%) | 5 (18.5%)      | 22 (81.5%) | 3.810   | 0.051   |
| Heredity |               |         |         |         |
| With, N (%) | 10 (37.0%)    | 17 (63.0%) | 0.238   | 0.626   |
| Without, N (%) | 20 (31.7%)   | 43 (68.3%) |         |         |
| Age, years | 27.6 ± 8.9    | 29.9 ± 9.9 | 1.170   | 0.282   |
| BDNF, ng/ml | 7.5 ± 2.7     | 9.9 ± 5.3 | 4.307a  | 0.042*  |
| PANSS score, mean ± SD | 23.7 ± 5.2 | 26.6 ± 6.5 | 3.302a  | 0.073   |
| Positive symptoms | 18.0 ± 5.5 | 18.6 ± 7.9 | 0.003a  | 0.956   |
| General symptoms | 33.0 ± 5.5 | 43.1 ± 12.2 | 15.671a | 0.000***|
| Total score | 74.8 ± 10.0   | 88.3 ± 20.7 | 8.731a  | 0.004***|

**BDNF; brain-derived neurotrophic factor; PANSS, Positive and Negative Syndrome Scale.**

*p < 0.05; **p < 0.001.

**Analysis of covariance (ANCOVA).**

In the analysis of covariance, we included demographic factors such as age, sex, and smoking status as covariates. Serum BDNF levels in patients with FEDN schizophrenia were significantly lower than those in healthy controls (p < 0.001).

**Clinical and Demographic Data and Serum Brain-Derived Neurotrophic Factor of the Patients With and Without Depressive Symptoms**

The Socio-demographic and clinical characteristics of patients with and without depressive symptoms are shown in Table 2. An analysis of variance (ANOVA) was used to compare the demographic features of these two subgroups. There was no significant difference in sex, age, years of education, smoking...
TABLE 3 | Correlations between BDNF and socio-demographic characteristics and PANSS scores in schizophrenia patients.

| Schizophrenia (n = 90) |  
|------------------------|------------------|
| Sex                    | 0.041 (0.744)    |
| Age                    | −0.099 (0.424)   |
| Age of onset           | −0.133 (0.283)   |
| Education              | −0.31 (0.802)    |
| Smoking status         | 0.026 (0.837)    |
| Heredity               | 0.207 (0.093)    |
| PANSS score            |                 |
| Negative symptoms      | 0.178 (0.150)    |
| General symptoms       | 0.238 (0.052)    |

*Values are shown as r (p value).*

The table shows correlations between BDNF levels and various socio-demographic characteristics and PANSS scores in schizophrenia patients. The correlations are presented as Pearson's correlation coefficient (r) and p-values. For example, there is a weak positive correlation between sex and BDNF levels (r = 0.041, p = 0.744).

status, or heredity between patients with and without depressive symptoms (all p > 0.05).

Moreover, no significant relationship was observed between serum BDNF levels and age, sex, education, smoking status, heredity, or age of onset in patients with and without depressive symptoms (all p > 0.05; Table 3).

In addition, analysis of covariance (ANCOVA) was conducted, considering smoking status as a covariate. Serum BDNF levels were shown to be higher in individuals with depressive symptoms compared to those without such symptoms (9.9 ± 5.3 vs. 7.5 ± 2.7 ng/mL; p < 0.05).

**Serum Brain-Derived Neurotrophic Factor Levels and Psychopathological Symptoms of Patients**

As shown in Table 2, patients without depression showed the following mean scores on PANSS: positive subscore, 23.7 ± 5.2; negative subscore, 18.0 ± 5.5; general psychopathology score, 33.0 ± 5.5, and PANSS total score, 74.8 ± 10.0. For patients with depression: positive subscore, 26.6 ± 6.5; negative subscore, 18.6 ± 7.9; general psychopathology score, 43.1 ± 12.2, and PANSS total score, 88.3 ± 20.7.

Smoking status was taken into account as a covariate in the analysis of covariance (ANCOVA). There were significant differences in PANSS general psychopathology (p < 0.001) and PANSS total scores (p = 0.001) between patients with and without depressive symptoms.

Further correlation analysis showed a significant association between BDNF levels and PANSS total scores (r = 0.328, p < 0.01; Figure 1). There was also a significant association between BDNF levels and positive symptom score (r = 0.342, p < 0.01; Figure 2) and further multiple linear regression affirmed this result (β = 0.342, 95% CI: 0.018–0.425, p = 0.005). However, no significant association was found between BDNF and other subscales (all p > 0.05; Table 3).

**Correlation Between Brain-Derived Neurotrophic Factor and Depressive Symptoms in Patients With Schizophrenia**

Correlation analyses did not show a significant association between BDNF levels and HAMD scores in all patients with schizophrenia (p > 0.05; Table 3).

**DISCUSSION**

In our current study, there were four main findings. (1) Serum BDNF levels were significantly lower in patients with FEDN schizophrenia than in healthy controls. (2) Serum BDNF levels were higher in FEDN schizophrenia patients with depressive symptoms than in patients without depressive symptoms. (3) There was a significant association between serum BDNF levels and positive symptoms (p < 0.01). (4) There was no significant association between serum BDNF levels and HAMD scores.

**Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia**

In this study, serum BDNF levels were lower in patients with FEDN schizophrenia than in healthy controls, confirming our
Association Between Brain-Derived Neurotrophic Factor and Clinical Symptoms

We found that patients without depressive symptoms performed lower on the PANSS total score and general subscore than patients with depressive symptoms. Additionally, we observed no difference in the positive subscore between the groups of patients, which is consistent with Calderon-Mediviella's previous study (61). There was also no difference in the negative subscore. Given that negative symptoms are less frequent in the initial year of schizophrenia, and peak between 2 and 5 years following the first admission, it is understandable that no difference was detected (62).

Another finding of this study was the significant correlation between serum BDNF levels and positive symptoms. In several previous studies, BDNF levels have been associated with both positive symptoms (63, 64) and negative symptoms (65). According to previous findings, BDNF and the dopaminergic system are intimately linked. There have been reports that BDNF and its receptor TrkB were expressed in the midbrain dopamine (DA) circuit (66). There is also further evidence to suggest that BDNF may enhance the release of DA (67).

Meanwhile, several theories have argued that uncoordinated DA signaling is to blame for positive symptoms such as delusions and hallucinations (68, 69). Therefore, we propose that the positive correlation between BDNF and positive symptom score observed in the current research was due to an aberrant interaction between the BDNF and DA systems, which warrants further investigation.

In the current study, no significant association was noted between serum BDNF levels and HAMD scores, which is consistent with some previous studies (70–72), but is not definitive (73). Nevertheless, to our knowledge, the current study is the first to include patients with first-episode schizophrenia as a study population. The discrepancy may be due to the sampling of patients at different stages of disease progression. Also, the relationship between serum BDNF levels and the severity of depression is complicated by many factors that cannot be ignored, such as seasonality, physical activity, and different methods of BDNF measurement (74–76). Accordingly, to determine how serum BDNF levels influence depressive symptoms in patients with FEDN schizophrenia, more research needs to be done.
symptoms in patients with FEDN schizophrenia. Patients with depressive symptoms in the early stages of schizophrenia were shown to have higher levels of BDNF in their serum. In addition, low serum BDNF levels were associated with positive symptoms of schizophrenia but not with depressive symptoms. The study’s relatively small sample size limited the extension of the findings. In follow-up studies, we will include more samples to confirm the findings in this study. Further longitudinal and prospective investigations may offer new venues for exploring the relationship between serum BDNF levels and depressive symptoms in patients with FEDN schizophrenia.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institute Review Board of Beijing Huilongguan Hospital. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Romm KL, Rossberg JJ, Berg AO, Barrett EA, Faerden A, Agartz I, et al. Depression and depressive symptoms in first episode psychosis. J Nerv Ment Dis. (2010) 198:67–71. doi: 10.1097/NMD.0b013e3181c81f0
2. Peitl V, Tefanovi M, Karlovi D. Depressive symptoms in schizophrenia and dopamine and serotonin gene polymorphisms. Prog Neuro Psychopharmacol Biol Psychiatry. (2017) 77:209.
3. Max I, Jimmy I, Attilio R, Mei SY, Zixu Y, Sara-Ann L, et al. Longitudinal cognitive changes in young individuals at ultrahigh risk for psychosis. JAMA Psychiatry. (2018) 75:329–39.
4. Samsom JN, Wong A. Schizophrenia and depression co-morbidity: what we have learned from animal models. Front Psychiatry. (2015) 6:13. doi: 10.3389/fpsyg.2015.00113
5. Dai J, DU X, Yin G, Zhang Y, Xia H, Li X, et al. Prevalence, demographic and clinical features of comorbid depressive symptoms in drug naïve patients with schizophrenia presenting with first episode psychosis. Schizophr Res. (2018) 193:182–7. doi: 10.1016/j.schres.2017.06.029
6. Hwang KA, Hwang HJ, Hwang YJ, Kim YJ. Mustard leaf extract suppresses psychological stress in chronic restraint stress–subjected mice by regulation of stress hormone, neurotransmitters, and apoptosis. Nutrients. (2020) 12:3640.
7. Paduchová Z, Katreněíková B, Vaváková M, Laubertová L, Nagyová Z, Garairova I, et al. The effect of omega-3 fatty acids on thromboxane, brain-derived neurotrophic factor, homocysteine, and vitamin d in depressive children and adolescents: randomized controlled trial. Nutrients. (2021) 13:13041095. doi: 10.3390/nu13041095
8. Rio M. BDNF and the central control of feeding: accidental bystander or essential player? Trends Neurosci. (2013) 36:83–90.
9. Kapczinski F, Frey BN, Kauer-Sant’Anna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurotherapeutics. (2008) 8:1101–13.
10. Hammans C, Neugebauer K, Kumar V, Mevissen L, Nickl-Jockschat T. BDNF serum levels are associated with white matter microstructure in schizophrenia - a pilot study. Front Psychiatry. (2020) 11:51. doi: 10.3389/fpsyg.2020.00031
11. Di Carlo P, Punzi G, Ursini G. Brain-derived neurotrophic factor and schizophrenia. Psychiatr Genet. (2019) 29:200–10. doi: 10.1097/ypg.0000000000000237
12. Man L, Lv X, Du XD, Yin G, Zhu X, Zhang Y, et al. Cognitive impairments and low BDNF Serum levels in first-episode drug-naïve patients with schizophrenia. Psychiatry Res. (2018) 263:1–6. doi: 10.1016/j.psychres.2018.02.034
13. Xiu MH, Wang DM, Du XD, Chen N, Tan SP, Tan YL, et al. Interaction of BDNF and cytokines in executive dysfunction in patients with chronic schizophrenia. Psychoneuroendocrinology. (2019) 108:110–7. doi: 10.1016/j.psyneuen.2019.06.006
14. Singh J, Verma R, Raghav R, Sarkar S, Sood M, Jain R. Brain-derived neurotrophic factor (BDNF) levels in first-episode schizophrenia and healthy controls: a comparative study. Asian J Psychiatr. (2020) 54:102370. doi: 10.1016/j.ajp.2020.102370
15. Xiu MH, Li Z, Chen DC, Chen S, Curbo ME, Wu HE, et al. Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with schizophrenia. Schizophr Bull. (2020) 46:1498–510. doi: 10.1093/schbul/sbaa062
16. Buckley PF, Pillai A, Howell KR. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry. (2011) 24:122–7.
17. Ray MT, Shannon Weickert C, Webster MJ. Decreased BDNF and TrkB Mrna expression in multiple cortical areas of patients with schizophrenia and mood disorders. Transl Psychiatry. (2014) 4:e389. doi: 10.1038/tp.2014.26
18. Han M, Deng C. BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. Neurosci Lett. (2020) 726:133870. doi: 10.1016/j.neulet.2018.10.015
19. To M, Sugimoto M, Saruta J, Yamamoto Y, Tsukinoki K. Cognitive dysfunction in a mouse model of cerebral ischemia influences salivary metabolomics. J Clin Med. (2021) 10:1698.
20. Nieto RR, Carrasco A, Corral S, Castillo R, Silva H. BDNF as a biomarker of cognition in schizophrenia/psychosis: an updated review. Front Psychiatry. (2021) 12:662407. doi: 10.3389/fpsyg.2021.662407

AUTHOR CONTRIBUTIONS

YW was responsible for study design, statistical analysis, and wrote the original draft. RY, YY, RP, SW, HW, YZ, and XF were involved in data curation, visualization, and investigation. NY, RL, JZ, SZ, XLZ, XL, ZL, and XBJ were responsible for the evolution of ideas, supervision, and review and editing of the manuscript. XD and XYZ participated in funding acquisition, conceptualization, resources, proposal writing, and editing the manuscript. All authors contributed to and have approved the final manuscript.

FUNDING

This work was supported by the Jiangsu Province High-level Health Talents “Six-one Project” (LGY2020042), “333 Project” of Jiangsu Province (BRA2020120), The Science and Technology Program of Suzhou (SS202069) and Key Diagnosis and treatment Program of Suzhou (LCZX202016).

ACKNOWLEDGMENTS

We would like to show their great gratitude to all the patients who participated in this study for their participation.
21. Qiao H, An SC, Xu C, Ma XM. Role of ProBDNF and BDNF in dendritic spine plasticity and depressive-like behaviors induced by an animal model of depression. Brain Res. (2017) 1665:29–37. doi: 10.1016/j.brainres.2017.02.020

22. Martins LS, Wiborg O, Holmes MC, Harris AP. BDNF(+/-) rats exhibit depressive phenotype and altered expression of genes relevant in mood disorders. Genes Brain Behav. (2019) 18:12546. doi: 10.1111/gbb.12546

23. Karge F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. (2002) 109:143–8.

24. Castrén E, Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. Neurobiol Dis. (2017) 97:119–26. doi: 10.1016/j.nbd.2016.07.010

25. Koo JW, Chaudhury D, Han MH, Nestler EJ. Role of mesolimbic brain-derived neurotrophic factor in depression. Biol Psychiatry. (2019) 86:738–48. doi: 10.1016/j.biopsych.2019.05.020

26. Reinhart V, Bove SE, Volfson D, Lewis DA, Kleiman RJ, Lanz TA. Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder. Neurobiol Dis. (2015) 77:220–7. doi: 10.1016/j.nbd.2015.03.011

27. Jiang H, Chen S, Li C, Lu N, Yue Y, Yin Y, et al. The serum protein levels of the Tpa-BDNF pathway are implicated in depression and antidepressant treatment. Transl Psychiatry. (2017) 7:e1079. doi: 10.1038/tp.2017.43

28. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatri Clin Neurosci. (2010) 64:341–57. doi: 10.1111/j.1440-1819.2010.02113.x

29. Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med. (2019) 49:1–9.

30. Wu ZW, Shi H, Chen DC, Chen S, Zhang XY. BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: a prospective 12-week longitudinal study. Psychoneuroendocrinology. (2020) 122:104879.

31. Zhang Y, Fang X, Fan W, Tang W, Cai J, Song L, et al. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study. Psychopharmacology. (2018) 235:1191–8.

32. Sun MM, Yang LM, Wang Y, Feng X, Cui KY, Liu LP, et al. BDNF Val66met polymorphism and anxiety/depression symptoms in schizophrenia in a chinese han population. Psychiatr Genet. (2013) 23:124–9. doi: 10.1097/YPG.0b013e32836e86

33. Han D, Sun D, Xiu M, Su X, Wang J, Li J, et al. Association between the improvement in depressive symptoms and serum BDNF levels in drug-naive first episode patients with schizophrenia: a longitudinal follow-up. Psychoneuroendocrinology. (2021) 133:105592. doi: 10.1016/j.psyneuen.2021.105592

34. Noto CS, Gadelta A, Belangero SI, Smith M, Aguiar B, Panizzuti B, et al. Association of biomarkers and depressive symptoms in schizophrenia. Neurosci Lett. (2011) 505:282–5.

35. Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. (2009) 373:2041–53. doi: 10.1016/S0140-6736(09)60600-7

36. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. (2011) 36:1437–53. doi: 10.1017/s1440-1819.11050914

37. Zimmermann M, Martinez-Cengotitabengoa M, et al. The efficacy of non-pharmacological interventions on brain-derived neurotrophic factor in schizophrenia: a systematic review and meta-analysis. Int J Mol Sci. (2016) 17:17101766. doi: 10.3390/ijms17101766

38. Klein AB, Williamson R, Santini MA, Clemmensen C, Eitrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropharmacological. (2011) 14:347–53. doi: 10.1017/s1441145710000738

39. Karege F, Schmid M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. (2002) 328:261–4. doi: 10.1016/s0304-3900(02)00529-3

40. Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. Theranostic biomarkers for schizophrenia. Int J Mol Sci. (2017) 18:18040733. doi: 10.3390/ijms18040733

41. Marenco S, Weinberger DR. The neurodevelopmental hypothesis of schizophrenia: relating a trail of evidence from cradle to grave. Dev Psychopathol. (2000) 12:301–27. doi: 10.1017/s0954579x00003138

42. Wisocki JS, Lewis DA. Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (Nt-3) in depressed patients with schizophrenia. Nord J Psychiatry. (2016) 70:267–71. doi: 10.3109/08039488.2015.1087592

43. Fang X, Chen Y, Wang Y, Ren J, Zhang C. Depressive symptoms in schizophrenia patients: a possible relationship between sirt1 and BDNF. Prog Neuropsychopharmacol Biol Psychiatry. (2019) 95:109673. doi: 10.1016/j.pnpbp.2019.109673

44. Reddy LF, Horan WP, Green MF. Motivational deficits and negative symptoms in schizophrenia: concepts and assessments. Curr Top Behav Neurosci. (2013) 27:357.

45. Albyakov Y, Aksoy N, Kuloglu M, Hashimoto K, Soydas Akyol E, Beyazrur M. Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome. Neuropsychiatr Dis Treat. (2015) 11:865–72.

46. Upthegrove R, Khandaker GM. Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Curr Top Behav Neurosci. (2020) 44:49–66. doi: 10.1007/978-3-319-2018_88

47. Sawa A, Sedlak TW. Oxidative stress and inflammation in schizophrenia. Schizophr Res. (2016) 176:1–2. doi: 10.1016/j.schres.2016.06.014

48. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. (2013) 74:400–9. doi: 10.1016/j.biopsych.2013.03.018

49. Capuzzi E, Bartoli F, Crocamo C, Clerici M, Carrà G. Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: a meta-analysis. Neurosci Biobehav Rev. (2017) 74:169–75. doi: 10.1016/j.neubiorev.2017.03.003

50. Scotton E, Colombo R, Reis JC, Possenborn GM, Hizo GH, Valiati FE, et al. BDNF Prevents central oxidative damage in a chronic unpredictable mild stress model: the possible role of Prez-1 in anhedonic behavior. Behav Brain Res. (2020) 378:112245. doi: 10.1016/j.bbr.2019.112245

51. Garcia-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martinez-Cengotitabengoa M, Pina-Camacho L, et al. Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative...
inflammatory hypothesis of schizophrenia. *Schizophr Bull.* (2014) 40:376–87. doi: 10.1093/schbul/bst001

60. Fraguas D, Díaz-Canéja CM, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A, Recio S, et al. Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis. *Schizophr Bull.* (2019) 45:742–51. doi: 10.1093/schbul/bby125

61. Calderon-Medivilla M, Vila-Badia R, Dolz M, Batjosa A, Barajas A, Del Cacho N, et al. Depressive symptoms and their relationship with negative and other psychotic symptoms in early onset psychosis. *Eur Child Adolesc Psychiatry.* (2021) 30:1383–90. doi: 10.1007/s00787-020-01618-0

62. Wolfram ADH, Leber A, Häfner H. Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. *Eur Arch Psychiatry Clin Neurosci.* (2016) 266:387–96.

63. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. Brain derived neurotrophic factor in first-episode psychosis. *Schizophr Res.* (2007) 91:1–5. doi: 10.1016/j.schres.2006.12.026

64. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. *Int J Neuropsychopharmacol.* (2010) 13:535–9. doi: 10.1017/s1461145709991015

65. Binford SS, Hubbard EM, Flowers E, Miller BL, Leutwyler H. Serum BDNF is positively associated with negative symptoms in older adults with schizophrenia. *Biol Res Nurs.* (2018) 20:63–9. doi: 10.1177/1099800417755634

66. Numan S, Seroogy KB. Expression of TrkB and TrkC Mrnas by adult midbrain dopamine neurons: a double-label in situ hybridization study. *J Comp Neurol.* (1999) 403:295–308. doi: 10.1002/(sici)1096-9861(19990118)403:33.0.co;2-1

67. Goggi J, Pullar IA, Carney SL, Bradford HF. Signalling pathways involved in the short-term potentiation of dopamine release by BDNF. *Brain Res.* (2003) 968:156–61. doi: 10.1016/s0006-8993(03)02234-0

68. McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and other psychotic symptoms in early onset psychosis. *Eur Child Adolesc Psychiatry.* (2011) 20:63–9. doi: 10.1177/1099800417735634

69. McCutcheon RA, Krystal JH, Howes OD. Measurement methods of BDNF levels in major depression: a qualitative systematic review of clinical trials. *Psychiatr Quart.* (2013) 84:485–97.

70. Molendijk ML, Haffmans JPM, Bus BAA, Philipp S, Penninx BWJH, Jos P, et al. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. *PLoS One.* (2012) 7:e48046. doi: 10.1371/journal.pone.0048046

71. Lako IM, Bruggeman R, Kneegtering H, Wiersma D, Schoevers RA, Slooff CJ, et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. *J Affect Disord.* (2011) 140:38–47.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wu, Du, Yang, Yue, Peng, Wu, Wang, Zhou, Fang, Yuan, Li, Zhang, Zou, Zhao, Lyu, Li, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.